Anti-™EM86A monoclonal antibody

Pre-made anti-™EM86A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to ™EM86A/™EM86A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2133-Ab-1/ GM-Tg-hg-IP2133-Ab-2Anti-Human ™EM86A monoclonal antibodyHuman
GM-Tg-rg-IP2133-Ab-1/ GM-Tg-rg-IP2133-Ab-2Anti-Rat ™EM86A monoclonal antibodyRat
GM-Tg-mg-IP2133-Ab-1/ GM-Tg-mg-IP2133-Ab-2Anti-Mouse ™EM86A monoclonal antibodyMouse
GM-Tg-cynog-IP2133-Ab-1/ GM-Tg-cynog-IP2133-Ab-2Anti-Cynomolgus/ Rhesus macaque ™EM86A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2133-Ab-1/ GM-Tg-felg-IP2133-Ab-2Anti-Feline ™EM86A monoclonal antibodyFeline
GM-Tg-cang-IP2133-Ab-1/ GM-Tg-cang-IP2133-Ab-2Anti-Canine ™EM86A monoclonal antibodyCanine
GM-Tg-bovg-IP2133-Ab-1/ GM-Tg-bovg-IP2133-Ab-2Anti-Bovine ™EM86A monoclonal antibodyBovine
GM-Tg-equg-IP2133-Ab-1/ GM-Tg-equg-IP2133-Ab-2Anti-Equine ™EM86A monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2133-Ab-1/ GM-Tg-hg-IP2133-Ab-2; GM-Tg-rg-IP2133-Ab-1/ GM-Tg-rg-IP2133-Ab-2;
GM-Tg-mg-IP2133-Ab-1/ GM-Tg-mg-IP2133-Ab-2; GM-Tg-cynog-IP2133-Ab-1/ GM-Tg-cynog-IP2133-Ab-2;
GM-Tg-felg-IP2133-Ab-1/ GM-Tg-felg-IP2133-Ab-2; GM-Tg-cang-IP2133-Ab-1/ GM-Tg-cang-IP2133-Ab-2;
GM-Tg-bovg-IP2133-Ab-1/ GM-Tg-bovg-IP2133-Ab-2; GM-Tg-equg-IP2133-Ab-1/ GM-Tg-equg-IP2133-Ab-2
Products NameAnti-™EM86A monoclonal antibody
Formatmab
Target Name™EM86A
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-™EM86A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2133-Ag-1Recombinant multi-species ™86A/ ™EM86A protein


    Target information

    Target IDGM-IP2133
    Target Name™EM86A
    Gene ID144110,67893,308602,703759,485407,101081162,532018,100057256
    Gene Symbol and Synonyms1810054O13Rik,RGD1305749,™EM86A
    Uniprot AccessionQ8N2M4,Q3MHQ7
    Uniprot Entry Name™86A_HUMAN,™86A_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000151117
    Target ClassificationN/A

    The target: ™EM86A, gene name: ™EM86A, also named as . Predicted to enable alkenylglycerophosphocholine hydrolase activity and alkenylglycerophosphoethanolamine hydrolase activity. Predicted to be integral component of membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.